Standard Biotools (LAB) Current Deferred Revenue (2010 - 2026)

Standard Biotools (LAB) has 17 years of Current Deferred Revenue data on file, last reported at $13.0 million in Q1 2026.

• On a quarterly basis, Current Deferred Revenue rose 1.81% year-over-year to $13.0 million in Q1 2026; TTM through Mar 2026 was $13.0 million, a 1.81% increase from a year earlier, with the FY2025 full-year figure at $38.9 million, down 9.31% from the prior year.
• Current Deferred Revenue for Q1 2026 stood at $13.0 million, down from $38.9 million in the prior quarter.
• Over the last five years, Current Deferred Revenue for LAB reached as high as $48.5 million in Q2 2024 and fell as low as $11.6 million in Q4 2023.
• Historically, Current Deferred Revenue has averaged $24.6 million across 5 years, with a median of $15.8 million in 2022.
• Across the five-year window, Current Deferred Revenue jumped 310.45% in 2024 and tumbled 73.28% in 2025, its largest moves.
• Year by year, Current Deferred Revenue stood at $14.6 million in 2022, then retreated by 20.54% to $11.6 million in 2023, then soared by 270.02% to $42.9 million in 2024, then fell by 9.31% to $38.9 million in 2025, then tumbled by 66.64% to $13.0 million in 2026.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $13.0 million in Q1 2026, $38.9 million in Q4 2025, and $40.1 million in Q3 2025.